Aditya Birla Sun Life Pharma & Healthcare Fund |
|
An open ended equity scheme investing in Pharma and Healthcare Services Sector. |
Data as on 30th September 2024 |
Fund Details |
Investment Objective |
|
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There is no assurance that the objective of the Scheme will be achieved. |
Fund Category |
Investment Style |
||
Thematic (Equity) |
Fund Manager | |
---|---|
Mr. Dhaval Shah & Mr. Dhaval Joshi |
Managing Fund Since | |
---|---|
July 11, 2019 & November 21, 2022 |
Experience in Managing the Fund | |
---|---|
5.2 Years & 1.9 Years |
Load Structure (as % of NAV) (Incl. for SIP) | |
---|---|
Entry Load | Nil |
Exit Load | For redemption/switchout of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil |
Total Expense Ratio (TER) | |
---|---|
Regular | 2.28% |
Direct | 0.92% |
Including additional expenses and goods and service tax on management fees. |
AUM ₹ | |
---|---|
Monthly Average AUM | 875.59 Crores |
AUM as on last day | 888.27 Crores |
Date of Allotment | |
---|---|
July 11, 2019 |
Benchmark | |
---|---|
BSE Healthcare TRI |
Other Parameters | |
---|---|
Standard Deviation | 16.02% |
Sharpe Ratio | 0.70 |
Beta | 0.96 |
Portfolio Turnover | 0.26 |
Treynor Ratio | 0.12 |
Average P/E | 38.58 |
Average P/BV | 5.54 |
Average Dividend Yield | 0.60 |
Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 6.76% (FBIL Overnight MIBOR as on 30 Sep 2024) for calculating Sharpe Ratio |
Application Amount for fresh subscription | |
---|---|
₹ 1,000 (plus in multiplies of ₹ 1) |
Min. Addl. Investment | |
---|---|
₹ 1,000 (plus in multiplies of ₹ 1) |
SIP | |
---|---|
Daily/Weekly/Monthly: Minimum ₹ 100/- |
NAV of Plans / Options ₹ | ||
---|---|---|
Regular Plan | Direct Plan | |
Growth | 32.3600 | 35.1600 |
IDCW$: | 22.7200 | 24.3100 |
$Income Distribution cum capital withdrawal |
PORTFOLIO |
Issuer | % to Net Assets |
Pharmaceuticals & Biotechnology | 71.98% |
Sun Pharmaceutical Industries Limited | 14.89% |
Cipla Limited | 7.82% |
Torrent Pharmaceuticals Limited | 7.44% |
Aurobindo Pharma Limited | 5.61% |
Ajanta Pharmaceuticals Limited | 4.66% |
Lupin Limited | 4.05% |
Alkem Laboratories Limited | 3.39% |
ALEMBIC PHARMACEUTICALS LIMITED | 3.26% |
Abbott India Limited | 2.62% |
J.B. Chemicals & Pharmaceuticals Limited | 2.60% |
Dr. Reddys Laboratories Limited | 2.42% |
IPCA Laboratories Limited | 2.33% |
Strides Pharma Science Limited | 2.12% |
Gland Pharma Limited | 1.97% |
Zydus Lifesciences Limited | 1.92% |
Issuer | % to Net Assets |
Emcure Pharmaceuticals Ltd | 1.47% |
Mankind Pharma Ltd | 1.27% |
Akums Drugs & Pharmaceuticals Ltd | 1.25% |
Sanofi India Limited | 0.88% |
Healthcare Services | 15.51% |
Apollo Hospitals Enterprise Limited | 5.99% |
Fortis Healthcare Limited | 5.04% |
Vijaya Diagnostic Centre Limited | 2.39% |
Jupiter Life Line Hospitals Ltd | 2.09% |
Insurance | 3.61% |
Medi Assist Healthcare Services Ltd | 1.94% |
Star Health & Allied Insurance Limited | 1.67% |
Chemicals & Petrochemicals | 0.91% |
Vinati Organics Limited | 0.91% |
Cash & Current Assets | 7.99% |
Total Net Assets | 100.00% |
Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes Co-Managed by Fund Managers is 1. Total Schemes managed by Mr. Dhaval Shah is 8. Total Schemes managed by Mr. Dhaval Joshi is 39. Click here to know more on performance of schemes managed by Fund Managers.
Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.
# Scheme Benchmark, ## Additional Benchmark
For SIP calculations above, the data assumes the investment of ₹ 10000/- on 1st day of every month or the subsequent working
day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment
of tax free IDCW declared at the then prevailing NAV. CAGR returns are computed after accounting for the cash flow by using
XIRR method (investment internal rate of return).Where Benchmark returns are not available, they have not been shown.
Past
performance may or may not be sustained in future. Returns greater than 1 year period are compounded annualized. IDCW
are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration.
This page is a part of the October 2024 Factsheet of Aditya Birla Sun Life Mutual Fund. Click on https://mutualfund.adityabirlacapital.com/empower/ for the digital factsheet.
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.